skip to content
CADTH Canadian Drug Expert Committee recommendation. Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) : indication : Parkinson's disease. Preview this item
ClosePreview this item
Checking...

CADTH Canadian Drug Expert Committee recommendation. Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) : indication : Parkinson's disease.

Author: CADTH Canadian Drug Expert Committee,; Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : CADTH, January 2018.
Series: Common drug review clinical review report.
Edition/Format:   eBook : Document : English : Version 1.0
Summary:
The CADTH Canadian Drug Expert Committee (CDEC) recommends that apomorphine hydrochloride (apomorphine) be reimbursed for the acute, intermittent treatment of hypomobility “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) in patients with advanced Parkinson's disease (PD), if the following criterion and conditions are met. Apomorphine should only be used as adjunctive therapy in patients  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: CADTH Canadian Drug Expert Committee,; Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 1090383967
Notes: "Final."
Description: 1 online resource (1 PDF file (7 pages)).
Series Title: Common drug review clinical review report.
Other Titles: Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.)

Abstract:

The CADTH Canadian Drug Expert Committee (CDEC) recommends that apomorphine hydrochloride (apomorphine) be reimbursed for the acute, intermittent treatment of hypomobility “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) in patients with advanced Parkinson's disease (PD), if the following criterion and conditions are met. Apomorphine should only be used as adjunctive therapy in patients who are receiving optimized PD therapy (levodopa and derivatives and dopaminergic agonists) and still experiencing “off” episodes. Patients treated with apomorphine should be under the care of a physician with experience in the diagnosis and management of PD. Reduction in price.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1090383967> # CADTH Canadian Drug Expert Committee recommendation. Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) : indication : Parkinson's disease.
    a schema:Book, schema:CreativeWork, schema:MediaObject ;
    library:oclcnum "1090383967" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/8985177669#Topic/antiparkinson_agents_therapeutic_use> ; # Antiparkinson Agents--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/8985177669#Topic/apomorphine_therapeutic_use> ; # Apomorphine--therapeutic use
    schema:about <http://experiment.worldcat.org/entity/work/data/8985177669#Topic/apomorphine_economics> ; # Apomorphine--economics
    schema:about <http://experiment.worldcat.org/entity/work/data/8985177669#Place/canada> ; # Canada.
    schema:about <http://experiment.worldcat.org/entity/work/data/8985177669#Topic/drug_costs> ; # Drug Costs
    schema:about <http://experiment.worldcat.org/entity/work/data/8985177669#Topic/antiparkinson_agents_economics> ; # Antiparkinson Agents--economics
    schema:about <http://experiment.worldcat.org/entity/work/data/8985177669#Topic/insurance_health_reimbursement> ; # Insurance, Health, Reimbursement
    schema:about <http://experiment.worldcat.org/entity/work/data/8985177669#Topic/parkinson_disease_drug_therapy> ; # Parkinson Disease--drug therapy
    schema:alternateName "Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.)" ;
    schema:author <http://experiment.worldcat.org/entity/work/data/8985177669#Organization/cadth_canadian_drug_expert_committee> ; # CADTH Canadian Drug Expert Committee,
    schema:bookEdition "Version 1.0." ;
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/8985177669#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
    schema:datePublished "2018" ;
    schema:description "The CADTH Canadian Drug Expert Committee (CDEC) recommends that apomorphine hydrochloride (apomorphine) be reimbursed for the acute, intermittent treatment of hypomobility “off” episodes (“end-of-dose wearing off” and unpredictable “on/off” episodes) in patients with advanced Parkinson's disease (PD), if the following criterion and conditions are met. Apomorphine should only be used as adjunctive therapy in patients who are receiving optimized PD therapy (levodopa and derivatives and dopaminergic agonists) and still experiencing “off” episodes. Patients treated with apomorphine should be under the care of a physician with experience in the diagnosis and management of PD. Reduction in price."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/8985177669> ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8985177669#Series/cadth_common_drug_review> ; # CADTH common drug review
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8985177669#Series/common_drug_review_clinical_review_report> ; # Common drug review clinical review report.
    schema:name "CADTH Canadian Drug Expert Committee recommendation. Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) : indication : Parkinson's disease."@en ;
    schema:productID "1090383967" ;
    schema:url <http://www.ncbi.nlm.nih.gov/books/NBK532998/> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1090383967> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/8985177669#Organization/cadth_canadian_drug_expert_committee> # CADTH Canadian Drug Expert Committee,
    a schema:Organization ;
    schema:name "CADTH Canadian Drug Expert Committee," ;
    .

<http://experiment.worldcat.org/entity/work/data/8985177669#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/8985177669#Series/cadth_common_drug_review> # CADTH common drug review
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1090383967> ; # CADTH Canadian Drug Expert Committee recommendation. Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) : indication : Parkinson's disease.
    schema:name "CADTH common drug review" ;
    .

<http://experiment.worldcat.org/entity/work/data/8985177669#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1090383967> ; # CADTH Canadian Drug Expert Committee recommendation. Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) : indication : Parkinson's disease.
    schema:name "Common drug review clinical review report." ;
    .

<http://experiment.worldcat.org/entity/work/data/8985177669#Topic/antiparkinson_agents_economics> # Antiparkinson Agents--economics
    a schema:Intangible ;
    schema:name "Antiparkinson Agents--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985177669#Topic/antiparkinson_agents_therapeutic_use> # Antiparkinson Agents--therapeutic use
    a schema:Intangible ;
    schema:name "Antiparkinson Agents--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985177669#Topic/apomorphine_economics> # Apomorphine--economics
    a schema:Intangible ;
    schema:name "Apomorphine--economics"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985177669#Topic/apomorphine_therapeutic_use> # Apomorphine--therapeutic use
    a schema:Intangible ;
    schema:name "Apomorphine--therapeutic use"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985177669#Topic/insurance_health_reimbursement> # Insurance, Health, Reimbursement
    a schema:Intangible ;
    schema:name "Insurance, Health, Reimbursement"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8985177669#Topic/parkinson_disease_drug_therapy> # Parkinson Disease--drug therapy
    a schema:Intangible ;
    schema:name "Parkinson Disease--drug therapy"@en ;
    .

<http://www.worldcat.org/title/-/oclc/1090383967>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/1090383967> ; # CADTH Canadian Drug Expert Committee recommendation. Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) : indication : Parkinson's disease.
    schema:dateModified "2019-03-22" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.